#Singapore #Pharma Solutions #Haier Biomedical #ISPE Singapore

Haier Biomedical Showcases Cutting-Edge Biostorage Technologies at ISPE Singapore 2026

In an impressive showcase at the ISPE Singapore Conference and Exhibition 2026, Haier Biomedical demonstrated its latest automated and digital solutions pivotal to pharmaceutical research and development, production, and quality control. The event, held at Suntec Singapore from August 20-21, featured Haier Biomedical's new technologies designed to enhance efficiency and reliability in pharmaceutical workflows.

A highlight of the exhibition was the debut of Haier's automated –80°C storage solution, which combines ultra-low temperature storage with intelligent sample management systems. This advancement is particularly crucial for companies and research institutions that manage high-value samples, as it enhances workflow efficiency and improves traceability. Accompanying this storage solution, the Pilot Freeze Dryer was also introduced, serving as a critical component to support laboratory research transitioning into manufacturing processes. Together, these technologies address the evolving needs of pharmaceutical companies from sample management to production.

During a dedicated Power Hour session, Haier Biomedical introduced its Smart RFID ULT Storage Solution, which seamlessly links physical samples to digital records throughout the storage process. This innovative system utilizes RFID labels to provide unique identities for samples, while compartment antennas and readers capture necessary data, eliminating the need for line-of-sight scanning. This thoughtful design enables improved data management of sample location and movement, ensuring all samples are easily retrievable.

The RFID-enhanced system supports various sample formats, including bottles, bags, tubes, and cryovials. It achieves adaptability through customizable shelves and holders, optimizing spatial use and further reducing search times and inventory discrepancies. Notably, this platform strengthens the chain-of-custody visibility essential for quality control and supply chain operations, aligning with the industry's shift towards automated and data-driven workflows.

As Haier Biomedical continues to establish itself as a leader in the biopharmaceutical infrastructure space, its broader portfolio on exhibition at ISPE Singapore encompassed not just storage solutions but also automation systems, ULT freezers, refrigerated centrifuges, and freeze-thaw systems, all crucial for pharmaceutical processes from research and development to production and quality control laboratories.

The company's strategic shift from supplying individual equipment to offering integrated, multi-product portfolios signifies its commitment to assist clients in building smarter, interconnected pharmaceutical R&D and production systems. The performance of Haier Biomedical in the recent first half of 2026 reflects this commitment, with revenue from pharmaceutical clients increasing by 23% year-over-year and laboratory solutions revenue growing by 19%. Furthermore, revenue from AI-related ventures accounted for 18%, indicating a significant uptick from the previous year.

Haier Biomedical continues to adapt its technologies and products, ensuring compliance with local regulations and the unique needs of customers. This adaptability not only echoes a customer-centric approach but also aims to empower pharmaceutical companies and research organizations to thrive in an increasingly complex and competitive landscape. By presenting advanced biostorage solutions at ISPE Singapore 2026, Haier Biomedical is reinforcing its role in enabling next-generation biopharmaceutical infrastructures.

For more information on Haier Biomedical's products and innovations, visit their official website.

Source: Haier Biomedical